Literature DB >> 23223041

Gene therapies advance, but some see manufacturing challenges.

Elie Dolgin.   

Abstract

Mesh:

Year:  2012        PMID: 23223041     DOI: 10.1038/nm1212-1718

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  2 in total

1.  Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection.

Authors:  Robert E Throm; Annastasia A Ouma; Sheng Zhou; Anantharaman Chandrasekaran; Timothy Lockey; Michael Greene; Suk See De Ravin; Morvarid Moayeri; Harry L Malech; Brian P Sorrentino; John T Gray
Journal:  Blood       Date:  2009-03-13       Impact factor: 22.113

2.  Capsid-expressing DNA in AAV vectors and its elimination by use of an oversize capsid gene for vector production.

Authors:  C L Halbert; M J Metzger; S-L Lam; A D Miller
Journal:  Gene Ther       Date:  2010-12-16       Impact factor: 5.250

  2 in total
  3 in total

Review 1.  Progress and challenges in viral vector manufacturing.

Authors:  Johannes C M van der Loo; J Fraser Wright
Journal:  Hum Mol Genet       Date:  2015-10-30       Impact factor: 6.150

2.  Absolute determination of single-stranded and self-complementary adeno-associated viral vector genome titers by droplet digital PCR.

Authors:  Martin Lock; Mauricio R Alvira; Shu-Jen Chen; James M Wilson
Journal:  Hum Gene Ther Methods       Date:  2014-02-14       Impact factor: 2.396

Review 3.  Product-Related Impurities in Clinical-Grade Recombinant AAV Vectors: Characterization and Risk Assessment.

Authors:  J Fraser Wright
Journal:  Biomedicines       Date:  2014-03-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.